Development and validation of a stability-indicating analytical method for the quantitation of oxytocin in pharmaceutical dosage forms by Chaibva, F A & Walker, Roderick
Development and validation of a stability-indicating analytical 
method for the quantitation of oxytocin in pharmaceutical dosage 
forms  
F.A. Chaibva and R.B. Walker 
Abstract 
A single stability-indicating assay for oxytocin (OT) in pharmaceutical dosage forms using gradient 
elution over 21 min has been reported in the literature. Furthermore, published and compendial 
methods for the analysis of OT containing dosage forms also involve using HPLC with gradient elution 
and complicated mobile phases that include hydrophobic ion pairing agents. A simple isocratic and 
stability-indicating assay was developed and validated. The conditions are as follows, column: 
Phenomenex® C18 Hypersil, 5 µm packing, 4.6 mm × 150 mm with acetonitrile–phosphate buffer (pH 5; 
0.08 M) (20:80) as the mobile phase with UV detection at 220 nm The method was found to be specific 
for OT in the presence of degradation products and chlorbutol (preservative) with an overall analytical 
run time of 16 min. Accuracy was determined to be 0.77–1.18% bias for all samples tested. Intra-assay 
precision (repeatability) was found to be 0.22–1.04%R.S.D. while the inter-day precision (intermediate 
precision) was found to be 1.27–1.68%R.S.D. for the samples studied. The calibration curve was found 
to be linear with the equation y = 1.81x + 0.02 and a linear regression coefficient of 0.9991 over the 
range 0.4–12.0 IU/ml. The LOD and the LOQ were determined to be 0.1 and 0.4 IU/ml, respectively. 
Syntocinon®, a commercially available dosage form of OT was assayed resulting in 100.5–106.6% 
recovery of the label claim and an average of 10.04 IU/ml.  
1. Introduction 
Oxytocin (OT) is a cyclic neurohypophyseal nonapeptide. The primary structure of OT is shown in Fig. 
1. OT possesses a 20 membered cyclic portion that is linked by a disulphide bridge between the two-
cysteine residues. It is synthesised by the hypothalamus and is released from the posterior lobe of the 
pituitary gland. It possesses uterotonic and galactogenic activity in mammals [1]. The main use of OT in 
clinical practice is the induction, and the augmentation of labour, control of post-partum haemorrhage 
and uterine hypotonicity in the third stage of labour. OT is also used to stimulate lactation [2].  
 
 
Fig. 1. Primary sequence of OT. 
 
The stability properties of OT have been previously reported by Nachtmann et al. [1]. The stability of 
OT is dependent on the pH and the optimal pH is between 3 and 5. In strongly acidic solutions, the 
peptide linkages undergo hydrolysis. Dimeric and polymeric compounds form under neutral and 
alkaline conditions and this occurs by the conversion of intramolecular disulphide bridges to 
intermolecular bridges resulting in the deactivation of OT [1]. Stability is important from a quality control 
perspective in the industry and therefore any analytical method developed should preferably be stability 
indicating.  
Previously reported assays for OT have mainly used HPLC as the preferred analytical tool. Krummen 
and Frei [3] and [4] described isocratic methods for the quantitation of OT in which both C8 and C18 
columns and relatively high flow rates in excess of 1.5 ml/min and up to 4.0 ml/min were used. 
However, a major disadvantage of using high flow rates is high backpressure on the analytical column 
[5], which has a negative impact on both the column and solvent delivery module, reducing the working 
lifetime. Pask-Hughes et al. published a method that uses sodium tetradecyl sulphate as a hydrophobic 
ion-pairing agent in the mobile phase [6]. The main disadvantage for the use of the ion pairing agents is 
the long time that is needed to equilibrate the column and the remove the ion pair agent from the 
column [7]. Ohta et al. [8] and Dudkiewicz-Wilczyńska et al. [9] published simple isocratic methods for 
the quantitating OT in dosage forms. Maxl and Siehr published a gradient method for the quality control 
of OT [10]. The compendial methods in the current United States Pharmacopeia [11] and British 
Pharmacopeia [12] are both gradient elution methods with phosphate buffer and acetonitrile. There is 
no information published in the aforementioned compendia with respect to the stability-indicating status 
of their methods. A stability indicating analytical method for the analysis of OT using gradient elution 
and a flow rate of 1.5 ml/min with resultant retention times of OT and chlorbutanol of 10.2 and 21.1 min, 
respectively, has been reported [13].  
The objective of these studies was to develop a simple isocratic method for the quantitative analysis of 
OT that was also stability indicating. The method that is reported is sensitive, selective, precise and 
accurate with a retention time of 4.7 min for OT. Furthermore analysis of a commercially available 
product containing OT revealed that the preservative, chlorbutol eluted at approximately 14.6 min.  
2. Experimental 
2.1. Reagents and chemicals 
OT was obtained from PolyPeptide Laboratories s.r.o. (Hostiva, Czech Republic). The potency was 
541 IU/mg. All reagents used were of analytical grade. Acetonitrile (HPLC grade, far UV) was 
purchased from Romil Ltd. (Cambridge, UK). Sodium hydroxide pellets and ortho-phosphoric acid 
(85%, w/w) were obtained from Merck Chemicals Ltd. (Johannesburg, RSA). HPLC grade water was 
purified using a Milli-Ro® -15 Water purification system (Millipore, Bedford, MA, USA), which is made 
up of a Super-C® carbon cartridge, two Ion-X® ion-exchange cartridges and an Organex-Q® cartridge. 
The water was filtered through a 0.22 µm Millipak® stack filter before use. Syntocinon® (Novartis, 
Johannesburg, South Africa), a locally available dosage form of OT at a concentration of 10 IU/ml was 
purchased from a local pharmacy.  
2.2. HPLC 
The modular HPLC system consisted of a Spectra-Physics Isochrom LC pump (Spectra-physics, San 
Jose, CA, USA), a Waters WISP 712 Autosampler (Waters Chromatography Division, Milford, MA, 
USA), a Linear Model 200 EZ Chrom UV–vis variable wavelength detector (Linear Instruments Corp., 
Reno, NV, USA) and a Model 561 strip chart recorder (Hitachi, Tokyo, Japan). A Phenomenex® 
(Torrance, CA, USA) Hypersil column, 5 µm, 4.6 mm × 150 mm was used at ambient temperature. 
Separation was achieved under isocratic conditions using a mobile phase of 20% (v/v) acetonitrile in 
80 mM phosphate buffer (pH 5) at a flow rate of 1.5 ml/min and UV detection at 220 nm. pH of 
solutions were measured using a Crison Model GLP 21 pH meter (Crison, Barcelona, Spain). The 
volume of injection was 20 µl.  
2.3. Standards and sample solutions 
Approximately 10 mg of OT (541 IU/mg) was accurately weighed and transferred into a 100 ml A-grade 
volumetric flask and was made up to volume with HPLC grade water. The concentration of the resultant 
solution was 54.1 IU/ml. The standard solutions were prepared in the concentration ranges 1–12 IU/ml 
using serial dilution of the stock solution using A-grade glassware.  
2.4. Preparation of buffers 
Buffer solutions were prepared by pipetting appropriate volumes of 85% ortho-phosphoric acid into A-
grade volumetric flasks and making up to volume with HPLC grade water. The pH was titrated to the 
required value using sodium hydroxide pellets.  
2.5. Method development and validation 
A previously published method [3] was optimised for the conditions in our laboratory in terms of the 
composition of the mobile phase, flow rate, pH and the molarity of the buffer. The method was 
validated according to USP [14] and ICH [15] and [16] guidelines. The validation parameters addressed 
were specificity, precision, accuracy, linearity, limits of detection and quantification and the stability of 
OT in the mobile phase.  
2.6. Stress testing of OT solution 
In order to ensure that the analytical assay was stability indicating, stress studies were performed as 
outlined by Snyder et al. [17]. All solutions prepared and used in these studies had an initial starting 
concentration of 10 IU/ml.  
2.6.1. Acid degradation studies 
A 2 ml of 0.1 M hydrochloric acid was added to 8 ml of a 10 IU/ml solution of OT. The resultant 
concentration was 8 IU/ml. This solution was allowed to stand for 1 h.  
2.6.2. Alkali degradation studies 
A 2 ml of 0.1 M sodium hydroxide was added to 8 ml of a 10 IU/ml solution of OT. The resultant 
concentration was 8 IU/ml. This solution was allowed to stand for 1 h.  
2.6.3. Temperature stress studies 
A 10 IU/ml OT solution was heated to and maintained at 50 °C for 10 min.  
2.6.4. Oxidation studies 
A 2 ml of a 3% hydrogen peroxide solution was added to 8 ml of a 10 IU/ml solution of OT. The 
resultant concentration was 8 IU/ml. This solution was placed in a dark locker for 2 h.  
2.6.5. Photostability studies 
A 10 ml OT solution at a concentration of 10 IU/ml in a clear volumetric flask was exposed to natural 
sunlight for 8 h. The solution was placed by a laboratory window for the duration of the experiment.  
2.7. Preparation of Syntocinon® for assay 
A 1.0 ml aliquot of the parenteral preparation was diluted to 5.0 ml with HPLC grade water and was 
assayed using the developed method.  
3. Results and discussion 
3.1. HPLC method development 
An HPLC method reported in the literature [3] was optimised for the conditions in our laboratory with 
respect to the choice of analytical column used, the composition of the mobile phase, pH and molarity 
in addition to mobile phase flow rate. The reported method used C8 columns at 67 mM phosphate 
buffer at pH 7 and flow rates of 2 or 3 ml/min.  
C8 columns are less hydrophobic than C18 columns. For organic non-polar molecules, the sample 
retention increases with increase in the length of the bonded phases [18]. However, OT is a very polar 
peptide that is ionised at physiological pH. In theory, comparing the equilibrium of OT between a C8 
column and the mobile phase and that between a C18 column and the mobile phase, there is going to 
be a higher ratio of OT in the mobile phase for the C18 column. For this reason OT would be eluted 
quicker from the C18 column than the C8 column. The longer retention of OT in the C8 column resulted 
in the need for higher flow rates or higher proportions of organic modifier being utilised in order to 
decrease the retention time of OT. It was our intention to use lower flow rates as high flow rates 
decrease the lifetime of both the column and the pump. Higher pressures in the column generate heat 
as the higher pressure is forcing the mobile phase through the column. The heat generated as a result 
degrades the column and reduces column efficiency and selectivity [5]. Increase in the content of the 
organic modifier resulted in a decrease in the retention time of the drug. At a composition of 30% (v/v) 
acetonitrile, OT eluted with the solvent front. At compositions less than 20% (v/v) acetonitrile, the 
retention time of OT was greater than 10 min at both flow rates of 1 and 1.5 ml/min, which were 
compared. The optimal conditions for OT were considered to be 20% (v/v) acetonitrile in buffer at a 
flow rate of 1.5 ml/min as this gave the peaks with the best shape and a retention time of 6.8 min. It is 
desirable to have retention times less than 10 min as this allows multiple analyses to be carried out in a 
reduced time. Changing the pH of the buffer affected both the retention times and the shape of the 
peaks produced. Decreasing the pH resulted in shorter retention times and gave sharper peaks. A pH 
of 5 was considered to be optimal as this gave a good compromise between retention time (5 min) and 
peak shape. The buffer molarity was changed and the choice of the optimal buffer strength was based 
on the theoretical plate number. A buffer strength of 80 mM gave the highest plate number while higher 
concentration resulted in a decrease in the plate number. The retention time shifted to 4.7 min. A 
typical representative chromatogram is shown in Fig. 2.  
 
 
Fig. 2. Typical chromatogram showing the separation of OT. 
 
3.2. Method validation 
3.2.1. Specificity and stress studies 
The results of the stress studies indicated the specificity of the method that has been developed. After 
exposure of OT solutions to stress conditions, an assay of OT was performed on the resultant 
solutions. Typical chromatograms obtained for these analyses are shown in Fig. 3, Fig. 4, Fig. 5 and 
Fig. 6.  
 
 
Fig. 3. Resultant chromatogram obtained following the exposure of OT solution to 0.1 M HCl showing the separation of OT 
and degradation products. 
 
  
Fig. 4. Resultant chromatogram obtained following the exposure of OT solution to 0.1 M NaOH showing the separation of 
OT and degradation products. 
 
 
 
Fig. 5. Resultant chromatogram obtained following the exposure of OT solution elevated temperatures showing the 
separation of OT peak and degradation products. 
  
 
Fig. 6. Resultant chromatogram obtained following the exposure of OT solution to 3% hydrogen peroxide solution showing 
the separation of OT and degradation products. 
 
It is clearly evident that when exposed to acidic conditions, OT undergoes degradation. The peaks of 
the resultant degradants were well resolved from the OT peak as shown in Fig. 3. OT is highly unstable 
in alkali conditions [1] and following exposure of OT to the alkali conditions previously described, 
almost all the OT had degraded with only a small peak being visible in the chromatogram as shown in 
Fig. 4. Following exposure to temperatures of 50 °C for 10 min the resultant peak of degradation 
product was well resolved from the OT peak and a typical chromatogram from these studies is shown 
in Fig. 5. OT also degraded in the presence of 3% hydrogen peroxide and the resultant OT peak was 
resolved from that of the degradation products as seen in Fig. 6. OT was found to be stable under the 
light conditions studied.  
 
The assay of a product must also show specificity with regard to the potential interference that might be 
a result of the presence of excipients in a formulation. In the case of Syntocinon®, chlorbutol is used as 
a preservative and the HPLC method that has been developed reveals that the preservative is well 
resolved from that of OT with a retention time of 14.6 min, thus indicating the assay procedure is 
specific for OT. A typical chromatogram developed during the analysis of Syntocinon® is shown in Fig. 
7.  
 
 
Fig. 7. Resultant chromatogram obtained following the analysis of Syntocinon® showing the separation of OT and chlorbutol. 
 
  
3.2.2. Linearity 
Calibration curves that were constructed for OT were linear over the range 0.4–12 IU/ml (see Table 1). 
The peak height (cm) of OT was plotted versus the concentration (IU/ml) of OT. The equation for the 
resultant calibration curve was y = 1.81x + 0.02 with a linear regression coefficient of 0.9991.  
Table 1. 
Linearity and precision data 
Concentration (n = 5) Peak height %R.S.D.
0 0 0 
0.4 0.53 5.17 
0.5 0.69 3.80 
1.0 1.81 1.24 
2.0 3.63 1.23 
4.0 7.79 0.54 
6.0 11.04 0.20 
8.0 14.45 0.35 
10.0 18.02 0.15 
12.0 21.48 0.31 
 
3.2.3. Precision 
Intra-assay precision (repeatability) and inter-day (intermediate) precision were determined. The 
analyses were performed using concentrations at three levels, 3, 7 and 11 IU/ml. Each concentration 
was analysed in triplicate (n = 3) and intra-assay precision was found to be less than 1.5%R.S.D. for all 
samples on all days. Inter-day precision %R.S.D. for analyses conducted on three separate days was 
found to be 1.51, 1.68 and 1.27%R.S.D. for the low, middle and high concentrations studied, 
respectively. The results of these studies are summarized in Table 2.  
Table 2. 
Intra-assay and inter-day precision 
OT 
(IU/ml) Day 1 Day 2 Day 3 
Intermediate 
precision 
 Peak height 
%R.S.D. 
(n = 3) 
Peak 
height 
%R.S.D. 
(n = 3) 
Peak 
height 
%R.S.D. 
(n = 3) %R.S.D. (n = 3) 
3 5.37 0.51 5.43 0.53 5.45 1.04 1.51 
7 12.56 0.33 12.83 0.45 12.98 0.22 1.68 
11 19.68 0.34 20.05 0.86 20.17 0.38 1.27 
  
3.2.4. Limit of detection (LOD) and limit of quantification (LOQ) 
The LOD was determined by using the signal to noise ratio method. The concentration that resulted in 
a signal to noise ratio of 3:1 was found to be 0.1 IU/ml and was determined to be the LOD. A signal to 
noise ratio of 10:1 was used to determine the LOQ and was the concentration that elicited a response 
that could be accurately and reliably measured. This concentration was found to be 0.4 IU/ml. The 
precision of the LOQ determination (n = 6) was found to be 4.84%R.S.D.  
3.2.5. Accuracy 
Accuracy was determined at three concentrations, similar to those used to assess the precision of the 
method. Each of the solutions was injected (n = 5) and the percentage bias was determined. The 
methods show a low percentage bias of less than 1.20% for all solutions tested and the results are 
summarized in Table 3.  
Table 3. 
Accuracy and percent bias 
Concentration (IU/ml) Determined concentration % Bias 
3 2.96 1.18 
7 6.95 0.77 
11 10.89 1.01 
 
3.3. Assay of Syntocinon®
An assay of the commercially available OT parenteral preparation (n = 3) injected in triplicate resulted 
in 100.2–106.6% of the label claim of 10.00 IU/ml and an average assay result of 10.38 IU/ml with the 
precision of the assay ranging between 0.76 and 1.49%R.S.D. for each set of determinations.  
4. Conclusion 
A simple isocratic and stability-indicating assay was developed and validated. The method is sensitive, 
selective, precise and accurate and was successfully applied to the analysis of commercially available 
OT products. The method has the advantage over a previously reported stability-indicating assay [13] 
in that it is isocratic method with a total analytical run time, when analysing OT in commercially 
available products, of approximately 16 min as opposed to the 21.1 min achieved using gradient elution 
chromatography.  
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